Rethinking risk for pneumococcal disease in adults: The role of risk stacking

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Pelton, Stephen I ^a,b   Shea, Kimberly M ^a   Weycker, Derek ^c   Farkouh, Raymond A ^d   Strutton, David R ^d   Edelsberg, John ^c  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c POLICY ANALYSIS INC PAI   (United States)

^d PFIZER INC   (United States)

Author keywords

Comorbidity; Pneumococcal infections; Pneumonia; Streptococcus pneumonia

Indexed keywords

ADULT; ADVISORY COMMITTEE; AGED; ARTICLE; COMORBIDITY; CROHN DISEASE; HEALTH CARE; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MIDDLE AGED; NEUROMUSCULAR DISEASE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEIZURE; STREPTOCOCCUS PNEUMONIA;

EID: 84978328524     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv020     Document Type: Article

References (13)

1. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014; 1:1-9.
2. Centers for Disease Control and Prevention (CDC). Use of 13-Valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61:816-9.
3. Pelton SI, Weycker D, Farkouh RA, et al. Risk of pneumococcal disease in children with chronic medical conditions in the era of pneumococcal conjugate vaccine. Clin Infect Dis 2014; 59:615-23.
4. Index Mundi. United States Age Structure, 2013. Available at: www.indexmundi.com/united_states/age_structure.html. Accessed 1 June 2014.
5. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813-20.
6. Bewick T, Sheppard C, Greenwood S, et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax 2012; 67:540-5.
7. Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal vaccination of children provokes new patterns of serotypes causing invasive pneumococcal disease in adults and children. Am J Med Sci 2013; 345: 112-20.
8. Boyd AR, Orihuela CJ. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis 2011; 2:487-500.
9. Hinojosa E, Boyd AR, Orihuela CJ. Age-associated inflammation and Toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J Infect Dis 2009; 200:546-54.
10. van de Garde EM, Hak E, Souverein PC, et al. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006; 61:957-61.
11. Mortensen EM, Restrepo MI, Anzueto A, et al. The effect of prior statin use on 30-day mortality for patients hospitalized with communityacquired pneumonia. Respir Res 2005; 6:82.
12. Roche JW, Boyd AR, Hinojosa E, et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 2010; 120: 627-35.
13. Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance Report, Emerging Infections Program Network: Streptococcus pneumoniae, 2007. Available at: http://www.cdc.gov/abcs/reportsfindings/survreports/spneu07.pdf. Accessed 26 June 2013.